{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T07:34:40Z","timestamp":1767598480360},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Key Research and Development Program of China","award":["No. 2016YFC1301202"],"award-info":[{"award-number":["No. 2016YFC1301202"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s11033-021-06248-6","type":"journal-article","created":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T17:02:30Z","timestamp":1615050150000},"page":"2729-2739","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["ANGPLT3 in cardio-metabolic disorders"],"prefix":"10.1007","volume":"48","author":[{"given":"Xin","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,6]]},"reference":[{"key":"6248_CR1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.metabol.2018.11.005","volume":"92","author":"J Vekic","year":"2019","unstructured":"Vekic J, Zeljkovic A, Stefanovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V (2019) Obesity and dyslipidemia. Metabolism 92:71\u201381","journal-title":"Metabolism"},{"key":"6248_CR2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cca.2020.01.015","volume":"503","author":"X Su","year":"2020","unstructured":"Su X, Peng D (2020) The exchangeable apolipoproteins in lipid metabolism and obesity. Clin Chim Acta 503:128\u2013135","journal-title":"Clin Chim Acta"},{"key":"6248_CR3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cca.2019.06.022","volume":"496","author":"X Su","year":"2019","unstructured":"Su X, Luo M, Tang X, Luo Y, Zheng X, Peng D, Investigators C-A (2019) Goals of non-high density lipoprotein cholesterol need to be adjusted in Chinese acute coronary syndrome patients: Findings from the CCC-ACS project. Clin Chim Acta 496:48\u201354","journal-title":"Clin Chim Acta"},{"issue":"9841","key":"6248_CR4","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","volume":"380","author":"BF Voight","year":"2012","unstructured":"Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Holm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart A, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PI, Klungel OH, Maitland-van der Zee AH, Peters BJ, de Boer A, Grobbee DE, Kamphuisen PW, Deneer VH, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WM, Boer JM, van der Schouw YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burtt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, Konig IR, Fischer M, Hengstenberg C, Ziegler A, Buysschaert I, Lambrechts D, Van de Werf F, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, Schafer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, O\u2019Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380(9841):572\u2013580","journal-title":"Lancet"},{"key":"6248_CR5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2018.07.004","volume":"276","author":"AR Tall","year":"2018","unstructured":"Tall AR (2018) Plasma high density lipoproteins: Therapeutic targeting and links to atherogenic inflammation. Atherosclerosis 276:39\u201343","journal-title":"Atherosclerosis"},{"issue":"1","key":"6248_CR6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2215\/CJN.13531119","volume":"15","author":"F Afshinnia","year":"2020","unstructured":"Afshinnia F, Pennathur S (2020) Lipids and Cardiovascular Risk with CKD. Clin J Am Soc Nephrol 15(1):5\u20137","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"6248_CR7","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12944-019-1080-x","volume":"18","author":"X Su","year":"2019","unstructured":"Su X, Kong Y, Peng D (2019) Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol. Lipids Health Dis 18(1):134","journal-title":"Lipids Health Dis"},{"issue":"7","key":"6248_CR8","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.bbalip.2014.03.013","volume":"1841","author":"S Kersten","year":"2014","unstructured":"Kersten S (2014) Physiological regulation of lipoprotein lipase. Biochim Biophys Acta 1841(7):919\u2013933","journal-title":"Biochim Biophys Acta"},{"issue":"13","key":"6248_CR9","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.1073\/pnas.1900983116","volume":"116","author":"AP Beigneux","year":"2019","unstructured":"Beigneux AP, Allan CM, Sandoval NP, Cho GW, Heizer PJ, Jung RS, Stanhope KL, Havel PJ, Birrane G, Meiyappan M, Gill JE, Murakami M, Miyashita K, Nakajima K, Ploug M, Fong LG, Young SG (2019) Lipoprotein lipase is active as a monomer. Proc Natl Acad Sci U S A 116(13):6319\u20136328","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"6248_CR10","doi-asserted-by":"crossref","first-page":"10360","DOI":"10.1073\/pnas.1820171116","volume":"116","author":"R Arora","year":"2019","unstructured":"Arora R, Nimonkar AV, Baird D, Wang C, Chiu CH, Horton PA, Hanrahan S, Cubbon R, Weldon S, Tschantz WR, Mueller S, Brunner R, Lehr P, Meier P, Ottl J, Voznesensky A, Pandey P, Smith TM, Stojanovic A, Flyer A, Benson TE, Romanowski MJ, Trauger JW (2019) Structure of lipoprotein lipase in complex with GPIHBP1. Proc Natl Acad Sci U S A 116(21):10360\u201310365","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"6248_CR11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/HCR.0b013e318192754e","volume":"29","author":"E Dembowski","year":"2009","unstructured":"Dembowski E, Davidson MH (2009) A review of lipid management in primary and secondary prevention. J Cardiopulm Rehabil Prev 29(1):2\u201312","journal-title":"J Cardiopulm Rehabil Prev"},{"key":"6248_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020431","author":"C Carbone","year":"2018","unstructured":"Carbone C, Piro G, Merz V, Simionato F, Santoro R, Zecchetto C, Tortora G, Melisi D (2018) Angiopoietin-Like Proteins in Angiogenesis. Inflammation and Cancer, Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms19020431","journal-title":"Inflammation and Cancer, Int J Mol Sci"},{"key":"6248_CR13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3389\/fendo.2018.00169","volume":"9","author":"M Luo","year":"2018","unstructured":"Luo M, Peng D (2018) ANGPTL8: An Important Regulator in Metabolic Disorders. Front Endocrinol (Lausanne) 9:169","journal-title":"Front Endocrinol (Lausanne)"},{"key":"6248_CR14","doi-asserted-by":"crossref","first-page":"104653","DOI":"10.1016\/j.phrs.2020.104653","volume":"153","author":"M Ruscica","year":"2020","unstructured":"Ruscica M, Zimetti F, Adorni MP, Sirtori CR, Lupo MG, Ferri N (2020) Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia. Pharmacol Res 153:104653","journal-title":"Pharmacol Res"},{"issue":"10","key":"6248_CR15","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.molmet.2017.06.014","volume":"6","author":"X Chi","year":"2017","unstructured":"Chi X, Britt EC, Shows HW, Hjelmaas AJ, Shetty SK, Cushing EM, Li W, Dou A, Zhang R, Davies BSJ (2017) ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase. Mol Metab 6(10):1137\u20131149","journal-title":"Mol Metab"},{"issue":"2","key":"6248_CR16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/ng814","volume":"30","author":"R Koishi","year":"2002","unstructured":"Koishi R, Ando Y, Ono M, Shimamura M, Yasumo H, Fujiwara T, Horikoshi H, Furukawa H (2002) Angptl3 regulates lipid metabolism in mice. Nat Genet 30(2):151\u2013157","journal-title":"Nat Genet"},{"issue":"1","key":"6248_CR17","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1038\/s41598-018-25237-7","volume":"8","author":"E Biterova","year":"2018","unstructured":"Biterova E, Esmaeeli M, Alanen HI, Saaranen M, Ruddock LW (2018) Structures of Angptl3 and Angptl4, modulators of triglyceride levels and coronary artery disease. Sci Rep 8(1):6752","journal-title":"Sci Rep"},{"issue":"19","key":"6248_CR18","doi-asserted-by":"crossref","first-page":"17281","DOI":"10.1074\/jbc.M109768200","volume":"277","author":"G Camenisch","year":"2002","unstructured":"Camenisch G, Pisabarro MT, Sherman D, Kowalski J, Nagel M, Hass P, Xie MH, Gurney A, Bodary S, Liang XH, Clark K, Beresini M, Ferrara N, Gerber HP (2002) ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo. J Biol Chem 277(19):17281\u201317290","journal-title":"J Biol Chem"},{"issue":"31","key":"6248_CR19","doi-asserted-by":"crossref","first-page":"5159","DOI":"10.2174\/0929867326666190621120523","volume":"27","author":"X Lu","year":"2020","unstructured":"Lu X (2020) Structure and Function of Angiopoietin-like Protein 3 (ANGPTL3) in Atherosclerosis. Curr Med Chem 27(31):5159\u20135174","journal-title":"Curr Med Chem"},{"key":"6248_CR20","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.atherosclerosis.2017.08.031","volume":"268","author":"YX Xu","year":"2018","unstructured":"Xu YX, Redon V, Yu H, Querbes W, Pirruccello J, Liebow A, Deik A, Trindade K, Wang X, Musunuru K, Clish CB, Cowan C, Fizgerald K, Rader D, Kathiresan S (2018) Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol. Atherosclerosis 268:196\u2013206","journal-title":"Atherosclerosis"},{"issue":"1\u20132","key":"6248_CR21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.mce.2006.05.005","volume":"256","author":"K Matsusue","year":"2006","unstructured":"Matsusue K, Miyoshi A, Yamano S, Gonzalez FJ (2006) Ligand-activated PPARbeta efficiently represses the induction of LXR-dependent promoter activity through competition with RXR. Mol Cell Endocrinol 256(1\u20132):23\u201333","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"6248_CR22","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1194\/jlr.M200367-JLR200","volume":"44","author":"R Kaplan","year":"2003","unstructured":"Kaplan R, Zhang T, Hernandez M, Gan FX, Wright SD, Waters MG, Cai TQ (2003) Regulation of the angiopoietin-like protein 3 gene by LXR. J Lipid Res 44(1):136\u2013143","journal-title":"J Lipid Res"},{"issue":"4","key":"6248_CR23","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s13105-013-0248-5","volume":"69","author":"HB Xiao","year":"2013","unstructured":"Xiao HB, Lu XY, Zhang HB, Sun ZL, Fang J (2013) Undaria pinnatifida soluble fiber regulates Angptl3-LPL pathway to lessen hyperlipidemia in mice. J Physiol Biochem 69(4):719\u2013725","journal-title":"J Physiol Biochem"},{"issue":"1\u20132","key":"6248_CR24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11010-008-9982-3","volume":"323","author":"Y Zou","year":"2009","unstructured":"Zou Y, Du H, Yin M, Zhang L, Mao L, Xiao N, Ren G, Zhang C, Pan J (2009) Effects of high dietary fat and cholesterol on expression of PPAR alpha, LXR alpha, and their responsive genes in the liver of apoE and LDLR double deficient mice. Mol Cell Biochem 323(1\u20132):195\u2013205","journal-title":"Mol Cell Biochem"},{"issue":"6","key":"6248_CR25","doi-asserted-by":"crossref","first-page":"e00160","DOI":"10.1042\/BSR20140115","volume":"34","author":"A Tikka","year":"2014","unstructured":"Tikka A, Soronen J, Laurila PP, Metso J, Ehnholm C, Jauhiainen M (2014) Silencing of ANGPTL 3 (angiopoietin-like protein 3) in human hepatocytes results in decreased expression of gluconeogenic genes and reduced triacylglycerol-rich VLDL secretion upon insulin stimulation. Biosci Rep 34(6):e00160","journal-title":"Biosci Rep"},{"issue":"11","key":"6248_CR26","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1194\/jlr.M028829","volume":"53","author":"L Ma","year":"2012","unstructured":"Ma L, Ballantyne CM, Belmont JW, Keinan A, Brautbar A (2012) Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia. J Lipid Res 53(11):2425\u20132428","journal-title":"J Lipid Res"},{"issue":"3","key":"6248_CR27","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s12253-014-9884-5","volume":"21","author":"K Sumegi","year":"2015","unstructured":"Sumegi K, Jaromi L, Magyari L, Kovesdi E, Duga B, Szalai R, Maasz A, Matyas P, Janicsek I, Melegh B (2015) Functional variants of lipid level modifier MLXIPL, GCKR, GALNT2, CILP2, ANGPTL3 and TRIB1 genes in healthy Roma and Hungarian populations. Pathol Oncol Res 21(3):743\u2013749","journal-title":"Pathol Oncol Res"},{"issue":"5","key":"6248_CR28","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/mgg3.450","volume":"6","author":"T Kunnas","year":"2018","unstructured":"Kunnas T, Solakivi T, Nikkari ST (2018) Association of low-density lipoprotein receptor-related protein 1 rs11613352 and angiopoietin-like 3 rs2131925 with hypertension in men-the Tampere adult population cardiovascular risk study. Mol Genet Genomic Med 6(5):828\u2013834","journal-title":"Mol Genet Genomic Med"},{"issue":"3","key":"6248_CR29","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/eurheartj\/ehr225","volume":"33","author":"A Angelakopoulou","year":"2012","unstructured":"Angelakopoulou A, Shah T, Sofat R, Shah S, Berry DJ, Cooper J, Palmen J, Tzoulaki I, Wong A, Jefferis BJ, Maniatis N, Drenos F, Gigante B, Hardy R, Laxton RC, Leander K, Motterle A, Simpson IA, Smeeth L, Thomson A, Verzilli C, Kuh D, Ireland H, Deanfield J, Caulfield M, Wallace C, Samani N, Munroe PB, Lathrop M, Fowkes FG, Marmot M, Whincup PH, Whittaker JC, de Faire U, Kivimaki M, Kumari M, Hypponen E, Power C, Humphries SE, Talmud PJ, Price J, Morris RW, Ye S, Casas JP, Hingorani AD (2012) Comparative analysis of genome-wide association studies signals for lipids, diabetes, and coronary heart disease: Cardiovascular Biomarker Genetics Collaboration. Eur Heart J 33(3):393\u2013407","journal-title":"Eur Heart J"},{"issue":"1","key":"6248_CR30","first-page":"70","volume":"119","author":"S Romeo","year":"2009","unstructured":"Romeo S, Yin W, Kozlitina J, Pennacchio LA, Boerwinkle E, Hobbs HH, Cohen JC (2009) Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest 119(1):70\u201379","journal-title":"J Clin Invest"},{"issue":"1","key":"6248_CR31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12944-018-0677-9","volume":"17","author":"WJ Li","year":"2018","unstructured":"Li WJ, Yin RX, Cao XL, Chen WX, Huang F, Wu JZ (2018) DOCK7-ANGPTL3 SNPs and their haplotypes with serum lipid levels and the risk of coronary artery disease and ischemic stroke. Lipids Health Dis 17(1):30","journal-title":"Lipids Health Dis"},{"key":"6248_CR32","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.2147\/NDT.S215387","volume":"15","author":"Q Gong","year":"2019","unstructured":"Gong Q, Ye L, Gui H, Liu J, Li H, Sun Q (2019) Association study of genetic variants of the ANGPTL3 gene and susceptibility to ischemic stroke. Neuropsychiatr Dis Treat 15:3015\u20133020","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"23","key":"6248_CR33","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","volume":"363","author":"K Musunuru","year":"2010","unstructured":"Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C, Garimella KV, Fisher S, Abreu J, Barry AJ, Fennell T, Banks E, Ambrogio L, Cibulskis K, Kernytsky A, Gonzalez E, Rudzicz N, Engert JC, DePristo MA, Daly MJ, Cohen JC, Hobbs HH, Altshuler D, Schonfeld G, Gabriel SB, Yue P, Kathiresan S (2010) Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med 363(23):2220\u20132227","journal-title":"N Engl J Med"},{"issue":"7","key":"6248_CR34","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/ATVBAHA.113.301397","volume":"33","author":"MR Robciuc","year":"2013","unstructured":"Robciuc MR, Maranghi M, Lahikainen A, Rader D, Bensadoun A, Oorni K, Metso J, Minicocci I, Ciociola E, Ceci F, Montali A, Arca M, Ehnholm C, Jauhiainen M (2013) Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. Arterioscler Thromb Vasc Biol 33(7):1706\u20131713","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"6248_CR35","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1161\/ATVBAHA.118.312021","volume":"39","author":"E Tikkanen","year":"2019","unstructured":"Tikkanen E, Minicocci I, Hallfors J, Di Costanzo A, D\u2019Erasmo L, Poggiogalle E, Donini LM, Wurtz P, Jauhiainen M, Olkkonen VM, Arca M (2019) Metabolomic Signature of Angiopoietin-Like Protein 3 Deficiency in Fasting and Postprandial State. Arterioscler Thromb Vasc Biol 39(4):665\u2013674","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"6248_CR36","doi-asserted-by":"crossref","first-page":"E1266","DOI":"10.1210\/jc.2012-1298","volume":"97","author":"I Minicocci","year":"2012","unstructured":"Minicocci I, Montali A, Robciuc MR, Quagliarini F, Censi V, Labbadia G, Gabiati C, Pigna G, Sepe ML, Pannozzo F, Lutjohann D, Fazio S, Jauhiainen M, Ehnholm C, Arca M (2012) Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization. J Clin Endocrinol Metab 97(7):E1266\u2013E1275","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"6248_CR37","doi-asserted-by":"crossref","first-page":"771","DOI":"10.5551\/jat.RV17023","volume":"25","author":"T Hirano","year":"2018","unstructured":"Hirano T (2018) Pathophysiology of Diabetic Dyslipidemia. J Atheroscler Thromb 25(9):771\u2013782","journal-title":"J Atheroscler Thromb"},{"key":"6248_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20051190","author":"H Yanai","year":"2019","unstructured":"Yanai H, Yoshida H (2019) Beneficial Effects of Adiponectin on Glucose and Lipid Metabolism and Atherosclerotic Progression: Mechanisms and Perspectives. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20051190","journal-title":"Int J Mol Sci"},{"key":"6248_CR39","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cca.2018.02.006","volume":"480","author":"PP He","year":"2018","unstructured":"He PP, Jiang T, OuYang XP, Liang YQ, Zou JQ, Wang Y, Shen QQ, Liao L, Zheng XL (2018) Lipoprotein lipase: Biosynthesis, regulatory factors, and its role in atherosclerosis and other diseases. Clin Chim Acta 480:126\u2013137","journal-title":"Clin Chim Acta"},{"issue":"2","key":"6248_CR40","doi-asserted-by":"crossref","first-page":"E271","DOI":"10.1152\/ajpendo.90920.2008","volume":"297","author":"H Wang","year":"2009","unstructured":"Wang H, Eckel RH (2009) Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab 297(2):E271\u2013E288","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"7","key":"6248_CR41","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1161\/ATVBAHA.117.309139","volume":"37","author":"C Wang","year":"2017","unstructured":"Wang C, Nishijima K, Kitajima S, Niimi M, Yan H, Chen Y, Ning B, Matsuhisa F, Liu E, Zhang J, Chen YE, Fan J (2017) Increased Hepatic Expression of Endothelial Lipase Inhibits Cholesterol Diet-Induced Hypercholesterolemia and Atherosclerosis in Transgenic Rabbits. Arterioscler Thromb Vasc Biol 37(7):1282\u20131289","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"6248_CR42","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1194\/jlr.M054882","volume":"56","author":"Y Wang","year":"2015","unstructured":"Wang Y, Gusarova V, Banfi S, Gromada J, Cohen JC, Hobbs HH (2015) Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion. J Lipid Res 56(7):1296\u20131307","journal-title":"J Lipid Res"},{"issue":"37","key":"6248_CR43","doi-asserted-by":"crossref","first-page":"11630","DOI":"10.1073\/pnas.1515374112","volume":"112","author":"Y Wang","year":"2015","unstructured":"Wang Y, McNutt MC, Banfi S, Levin MG, Holland WL, Gusarova V, Gromada J, Cohen JC, Hobbs HH (2015) Hepatic ANGPTL3 regulates adipose tissue energy homeostasis. Proc Natl Acad Sci U S A 112(37):11630\u201311635","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6248_CR44","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.metabol.2017.07.002","volume":"75","author":"E Sondergaard","year":"2017","unstructured":"Sondergaard E, Johansen RF, Jensen MD, Nielsen S (2017) Postprandial VLDL-TG metabolism in type 2 diabetes. Metabolism 75:25\u201335","journal-title":"Metabolism"},{"issue":"6 Pt 2","key":"6248_CR45","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1262-3636(08)74600-7","volume":"34","author":"J Capeau","year":"2008","unstructured":"Capeau J (2008) Insulin resistance and steatosis in humans. Diabetes Metab 34(6 Pt 2):649\u2013657","journal-title":"Diabetes Metab"},{"issue":"12","key":"6248_CR46","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrendo.2017.119","volume":"13","author":"S Kersten","year":"2017","unstructured":"Kersten S (2017) Angiopoietin-like 3 in lipoprotein metabolism. Nat Rev Endocrinol 13(12):731\u2013739","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"6248_CR47","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S0006-291X(02)03058-9","volume":"301","author":"M Shimamura","year":"2003","unstructured":"Shimamura M, Matsuda M, Kobayashi S, Ando Y, Ono M, Koishi R, Furukawa H, Makishima M, Shimomura I (2003) Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes. Biochem Biophys Res Commun 301(2):604\u2013609","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"6248_CR48","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12020-015-0838-9","volume":"52","author":"A Tikka","year":"2016","unstructured":"Tikka A, Jauhiainen M (2016) The role of ANGPTL3 in controlling lipoprotein metabolism. Endocrine 52(2):187\u2013193","journal-title":"Endocrine"},{"issue":"1","key":"6248_CR49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/1871529X18666180302113713","volume":"18","author":"S Guo","year":"2018","unstructured":"Guo S, Li L, Yin H (2018) Cholesterol Homeostasis and Liver X Receptor (LXR) in Atherosclerosis. Cardiovasc Hematol Disord Drug Targets 18(1):27\u201333","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"issue":"8","key":"6248_CR50","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41574-018-0037-x","volume":"14","author":"B Wang","year":"2018","unstructured":"Wang B, Tontonoz P (2018) Liver X receptors in lipid signalling and membrane homeostasis. Nat Rev Endocrinol 14(8):452\u2013463","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"6248_CR51","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1194\/jlr.M500005-JLR200","volume":"46","author":"H Ge","year":"2005","unstructured":"Ge H, Cha JY, Gopal H, Harp C, Yu X, Repa JJ, Li C (2005) Differential regulation and properties of angiopoietin-like proteins 3 and 4. J Lipid Res 46(7):1484\u20131490","journal-title":"J Lipid Res"},{"issue":"24","key":"6248_CR52","doi-asserted-by":"crossref","first-page":"21344","DOI":"10.1074\/jbc.M213202200","volume":"278","author":"T Inaba","year":"2003","unstructured":"Inaba T, Matsuda M, Shimamura M, Takei N, Terasaka N, Ando Y, Yasumo H, Koishi R, Makishima M, Shimomura I (2003) Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor. J Biol Chem 278(24):21344\u201321351","journal-title":"J Biol Chem"},{"issue":"110\u2013111","key":"6248_CR53","first-page":"1742","volume":"58","author":"H Yu","year":"2011","unstructured":"Yu H, Zhang H, Li D, Xue H, Pan C, Zhao S, Wang L (2011) Effects of ANGPTL3 antisense oligodeoxynucleotides transfection on the cell growths and invasion of human hepatocellular carcinoma cells. Hepatogastroenterology 58(110\u2013111):1742\u20131746","journal-title":"Hepatogastroenterology"},{"issue":"43","key":"6248_CR54","doi-asserted-by":"crossref","first-page":"41804","DOI":"10.1074\/jbc.M302861200","volume":"278","author":"M Ono","year":"2003","unstructured":"Ono M, Shimizugawa T, Shimamura M, Yoshida K, Noji-Sakikawa C, Ando Y, Koishi R, Furukawa H (2003) Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo. J Biol Chem 278(43):41804\u201341809","journal-title":"J Biol Chem"},{"issue":"3","key":"6248_CR55","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/MOL.0b013e32832ac026","volume":"20","author":"AP Beigneux","year":"2009","unstructured":"Beigneux AP, Weinstein MM, Davies BS, Gin P, Bensadoun A, Fong LG, Young SG (2009) GPIHBP1 and lipolysis: an update. Curr Opin Lipidol 20(3):211\u2013216","journal-title":"Curr Opin Lipidol"},{"issue":"7","key":"6248_CR56","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.tem.2016.04.013","volume":"27","author":"LG Fong","year":"2016","unstructured":"Fong LG, Young SG, Beigneux AP, Bensadoun A, Oberer M, Jiang H, Ploug M (2016) GPIHBP1 and Plasma Triglyceride Metabolism. Trends Endocrinol Metab 27(7):455\u2013469","journal-title":"Trends Endocrinol Metab"},{"issue":"18","key":"6248_CR57","doi-asserted-by":"crossref","first-page":"11942","DOI":"10.1074\/jbc.M809802200","volume":"284","author":"MH Yau","year":"2009","unstructured":"Yau MH, Wang Y, Lam KS, Zhang J, Wu D, Xu A (2009) A highly conserved motif within the NH2-terminal coiled-coil domain of angiopoietin-like protein 4 confers its inhibitory effects on lipoprotein lipase by disrupting the enzyme dimerization. J Biol Chem 284(18):11942\u201311952","journal-title":"J Biol Chem"},{"issue":"36","key":"6248_CR58","doi-asserted-by":"crossref","first-page":"27561","DOI":"10.1074\/jbc.M110.144279","volume":"285","author":"J Liu","year":"2010","unstructured":"Liu J, Afroza H, Rader DJ, Jin W (2010) Angiopoietin-like protein 3 inhibits lipoprotein lipase activity through enhancing its cleavage by proprotein convertases. J Biol Chem 285(36):27561\u201327570","journal-title":"J Biol Chem"},{"issue":"11","key":"6248_CR59","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11883-017-0678-6","volume":"19","author":"AJ Kattoor","year":"2017","unstructured":"Kattoor AJ, Pothineni NVK, Palagiri D, Mehta JL (2017) Oxidative Stress in Atherosclerosis. Curr Atheroscler Rep 19(11):42","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"6248_CR60","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s12944-017-0625-0","volume":"16","author":"J Peng","year":"2017","unstructured":"Peng J, Luo F, Ruan G, Peng R, Li X (2017) Hypertriglyceridemia and atherosclerosis. Lipids Health Dis 16(1):233","journal-title":"Lipids Health Dis"},{"issue":"2","key":"6248_CR61","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/MED.0000000000000468","volume":"26","author":"G Generoso","year":"2019","unstructured":"Generoso G, Janovsky C, Bittencourt MS (2019) Triglycerides and triglyceride-rich lipoproteins in the development and progression of atherosclerosis. Curr Opin Endocrinol Diabetes Obes 26(2):109\u2013116","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"4","key":"6248_CR62","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","volume":"118","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG (2016) Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology. Genetics, and Biology, Circ Res 118(4):547\u2013563","journal-title":"Genetics, and Biology, Circ Res"},{"issue":"3","key":"6248_CR63","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","volume":"377","author":"FE Dewey","year":"2017","unstructured":"Dewey FE, Gusarova V, Dunbar RL, O\u2019Dushlaine C, Schurmann C, Gottesman O, McCarthy S, Van Hout CV, Bruse S, Dansky HM, Leader JB, Murray MF, Ritchie MD, Kirchner HL, Habegger L, Lopez A, Penn J, Zhao A, Shao W, Stahl N, Murphy AJ, Hamon S, Bouzelmat A, Zhang R, Shumel B, Pordy R, Gipe D, Herman GA, Sheu WHH, Lee IT, Liang KW, Guo X, Rotter JI, Chen YI, Kraus WE, Shah SH, Damrauer S, Small A, Rader DJ, Wulff AB, Nordestgaard BG, Tybjaerg-Hansen A, van den Hoek AM, Princen HMG, Ledbetter DH, Carey DJ, Overton JD, Reid JG, Sasiela WJ, Banerjee P, Shuldiner AR, Borecki IB, Teslovich TM, Yancopoulos GD, Mellis SJ, Gromada J, Baras A (2017) Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. N Engl J Med 377(3):211\u2013221","journal-title":"N Engl J Med"},{"issue":"6","key":"6248_CR64","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","volume":"140","author":"Z Ahmad","year":"2019","unstructured":"Ahmad Z, Banerjee P, Hamon S, Chan KC, Bouzelmat A, Sasiela WJ, Pordy R, Mellis S, Dansky H, Gipe DA, Dunbar RL (2019) Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia. Circulation 140(6):470\u2013486","journal-title":"Circulation"},{"issue":"3","key":"6248_CR65","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","volume":"377","author":"D Gaudet","year":"2017","unstructured":"Gaudet D, Gipe DA, Pordy R, Ahmad Z, Cuchel M, Shah PK, Chyu KY, Sasiela WJ, Chan KC, Brisson D, Khoury E, Banerjee P, Gusarova V, Gromada J, Stahl N, Yancopoulos GD, Hovingh GK (2017) ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia. N Engl J Med 377(3):296\u2013297","journal-title":"N Engl J Med"},{"issue":"3","key":"6248_CR66","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1161\/CIRCRESAHA.118.313171","volume":"124","author":"RA Hegele","year":"2019","unstructured":"Hegele RA, Tsimikas S (2019) Lipid-Lowering Agents. Circ Res 124(3):386\u2013404","journal-title":"Circ Res"},{"issue":"16","key":"6248_CR67","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","volume":"69","author":"NO Stitziel","year":"2017","unstructured":"Stitziel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE, Natarajan P, Klarin D, Emdin CA, Zekavat SM, Nomura A, Erdmann J, Schunkert H, Samani NJ, Kraus WE, Shah SH, Yu B, Boerwinkle E, Rader DJ, Gupta N, Frossard PM, Rasheed A, Danesh J, Lander ES, Gabriel S, Saleheen D, Musunuru K, Kathiresan S, Promis I, Myocardial Infarction Genetics Consortium (2017) ANGPTL3 Deficiency and Protection Against Coronary Artery Disease. J Am Coll Cardiol 69(16):2054\u20132063","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"6248_CR68","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s40618-019-01019-4","volume":"42","author":"I Dicembrini","year":"2019","unstructured":"Dicembrini I, Giannini S, Ragghianti B, Mannucci E, Monami M (2019) Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Endocrinol Invest 42(9):1029\u20131039","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"6248_CR69","doi-asserted-by":"crossref","first-page":"e010932","DOI":"10.1161\/JAHA.118.010932","volume":"8","author":"MD Shapiro","year":"2019","unstructured":"Shapiro MD, Minnier J, Tavori H, Kassahun H, Flower A, Somaratne R, Fazio S (2019) Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab. J Am Heart Assoc 8(4):e010932","journal-title":"J Am Heart Assoc"},{"issue":"10106","key":"6248_CR70","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","volume":"390","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS, Investigators F (2017) Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet 390(10106):1962\u20131971","journal-title":"Lancet"},{"issue":"4","key":"6248_CR71","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","volume":"137","author":"MP Bonaca","year":"2018","unstructured":"Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS (2018) Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation 137(4):338\u2013350","journal-title":"Circulation"},{"issue":"3","key":"6248_CR72","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","volume":"377","author":"MJ Graham","year":"2017","unstructured":"Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, Yu R, Hurh E, Paz E, McEvoy BW, Baker BF, Pham NC, Digenio A, Hughes SG, Geary RS, Witztum JL, Crooke RM, Tsimikas S (2017) Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. N Engl J Med 377(3):222\u2013232","journal-title":"N Engl J Med"},{"issue":"3","key":"6248_CR73","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","volume":"72","author":"RS Rosenson","year":"2018","unstructured":"Rosenson RS, Hegele RA, Fazio S, Cannon CP (2018) The Evolving Future of PCSK9 Inhibitors. J Am Coll Cardiol 72(3):314\u2013329","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"6248_CR74","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41569-018-0107-8","volume":"16","author":"MS Sabatine","year":"2019","unstructured":"Sabatine MS (2019) PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol 16(3):155\u2013165","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"6248_CR75","doi-asserted-by":"crossref","first-page":"158791","DOI":"10.1016\/j.bbalip.2020.158791","volume":"1865","author":"H Ruhanen","year":"2020","unstructured":"Ruhanen H, Haridas PAN, Jauhiainen M, Olkkonen VM (2020) Angiopoietin-like protein 3, an emerging cardiometabolic therapy target with systemic and cell-autonomous functions. Biochim Biophys Acta Mol Cell Biol Lipids 1865(12):158791","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-021-06248-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-021-06248-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-021-06248-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T09:43:30Z","timestamp":1618998210000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-021-06248-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["6248"],"URL":"https:\/\/doi.org\/10.1007\/s11033-021-06248-6","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"5 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The sole author has no other competing interests or conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}